Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ramelteon in Subjects With Chronic Insomnia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Participant has participated in an allowed Ramelteon study and has completed all final visit procedures for the previous study within 21 days of the Treatment Initiation Visit for this study.~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.~* Investigator believes that participant requires long-term treatment for insomnia.~* Primary insomnia as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised for at least 3 months and a history of daytime complaint(s) associated with disturbed sleep.~* Subjective sleep latency greater than or equal to 45 minutes and a subjective total sleep time less than or equal to 6.5 hours per night for at least 3 nights during the week of the Baseline Lead-in Period.~* Habitual bedtime is between 8:30PM and 12:00AM.~* Body mass index between 18 and 34, inclusive.~Exclusion Criteria~* Known hypersensitivity to Ramelteon or related compounds, including melatonin.~* Participated in any other investigational study, and/or taken any investigational drug within 30 days or five half-lives prior to Day 1 of study medication, whichever is longer. The only exception to this is prior participation in an allowed Ramelteon study.~* Sleep schedule changes required by employment (eg, shift worker) within three months prior to Day 1 of study medication, or has flown across greater than three time zones within seven days prior to screening.~* Participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to Day 1 of study medication.~* Ever had a history of seizures, sleep apnea, chronic obstructive pulmonary disease, restless leg syndrome, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.~* History of psychiatric disorder (including anxiety or depression) within the past 12 months.~* History of drug addiction or drug abuse with the past 12 months.~* History of alcohol abuse within the past 12 months, as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised and/or regularly consumes 4 or more alcoholic drinks per day.~* Current significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, or metabolic disease, unless currently controlled and stable with protocol-allowed medication 30 days prior to Day 1 of study medication.~* Uses tobacco products during nightly awakenings.~* Any clinically important abnormal finding as determined by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.~* Positive hepatitis panel.~* Any additional condition(s) that in the Investigator's opinion would:~  * affect sleep/wake function~ * prohibit the subject from completing the study, or~ * not be in the best interest of the subject to participate in the study.~* Morning serum cortisol at the Baseline visit of less than 7.0 micro-g per dl.~* Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication, including:~  * Anxiolytics~ * Hypnotics~ * Antidepressants~ * Anticonvulsants~ * Sedating H1 antihistamines~ * Systemic steroids~ * Respiratory stimulants (eg, theophylline)~ * Decongestants~ * Over-the-counter and prescription stimulants~ * Over-the-counter and prescription diet aids~ * Central nervous system active drugs~ * Narcotic analgesics~ * Beta blockers~ * St. John's Wort~ * Kava-kava~ * Gingko biloba~ * Melatonin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ramelteon 8 mg QD (Type: EXPERIMENTAL): None
- Ramelteon 16 mg QD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).